Cancer research
Impact of Minimal Residual Disease on Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
Research published in Haematologica has shed light on the impact of minimal residual disease (MRD) on the outcome of hematopoietic stem cell transplantation (HSCT) for childhood acute lymphoblastic leukemia (ALL). The study, conducted within the international phase-III FORUM trial, found that MRD positivity was associated with worse event-free survival (EFS)